Amarin Corp Plc (AMRN)

[Tseven]

I would change the wording on your last sentence. Not the market. The institutional investor. As you know this stock is in the bottom 10 percent owned by institutions. Remove sarissa and it is bottom 5. If that number was double or triple the stock would be trading much higher. Now the question is why do the institutional investors stay clear of the stock. No matter if you are a mutual or hedge fund you are benchmarked on something. For the long only mutual if you run a bio pharma fund you can be benchmarked on any of the many pharma bio index etfs like ibb xbi etc. That is all they care about. The bonus is based on performance verses some index. Hedge fund the same but much more complicated as they usually have longs hedged by multiple legged options. So they dont think it is a value destroyer just their are better potential out performers availabe. Think about the huge winners in the bio space over the last few years and what moves the stocks. Rarely it is an eps beat or low pe or peg ratio. Probably 90 percent of the time it is results of a successful trial. Look at the majority of m and a last year. Probably 80 percent have zero revenues. Buying the pipeline.Small cap bio does not trade like a consumer staple. Investors rarely look and say selling at a low pe or cash. Verses market cap. I had a report in april that showed 45 percen of all small cap bio stocks had larger cash values than market cap. Sure that has changed drastically since the xbi has made a huge run. Bio performance equal pipeline and patents.